Chemours: Dividend Cut May Signal A Bottom Is Near
Chemours has faced significant challenges, including weak demand, excess supply, and poor earnings, leading to a 50% drop in stock value and a 9% after-hours plunge. Despite weak performance, Chemours is nearing a potential buy point due to its free cash flow generation and strategic dividend cut to safeguard its balance sheet. CC expects sequential sales growth and a 40-45% increase in adjusted EBITDA, but the outlook remains cautious due to economic uncertainties and tariffs.
Chemours (CC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q1 Earnings Miss Estimates
Chemours (CC) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.32 per share a year ago.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Chemours (CC) Down 14% Since Last Earnings Report?
Chemours (CC) reported earnings 30 days ago. What's next for the stock?
Chemours Forms Partnership With Energy Fuels to Establish Supply Chain
CC & Energy Fuels team up to expand rare earth and critical mineral supply chains in the U.S. domestic market.
Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial
CC partners with industry leaders to address the data center cooling gap by conducting Opteon 2P50 product trials.
Chemours' Earnings Outpace Estimates, Revenues Miss in Q4
CC's sales fall modestly as a drop in pricing is largely offset by a gain in volume, while the currency impact remains unchanged in Q4.
The Long-Term Upside For Chemours Company After Q4 2024
I've been investing in Chemours for years, despite recent accounting irregularities and share price decline since before 2024. Chemours, a leader in the titanium dioxide sector, also excels in new refrigerants like Opteon due to regulatory changes. Despite recent poor returns, I remain confident in Chemours' fundamentals and long-term potential, especially after 4Q24.
The Chemours Company (CC) Q4 2024 Earnings Call Transcript
The Chemours Company (NYSE:CC ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Brandon Ontjes - VP of IR Denise Dignam - President and CEO Shane Hostetter - SVP and CFO Conference Call Participants Arun Viswanathan - RBC Capital Markets Josh Spector - UBS Hassan Ahmed - Alembic Global Advisors John McNulty - BMO Vincent Andrews - Morgan Stanley John Roberts - Mizuho Laurence Alexander - Jefferies Jeff Zekauskas - JPMorgan Pete Osterland - Truist Operator Good morning. My name is Michelle, and I will be your conference operator today.
Chemours (CC) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Q4 Earnings Beat Estimates
Chemours (CC) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.31 per share a year ago.
